natgillin/translations-raw huggingface dataset:
Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for HBV infection during treatment. 
Bolnike je treba pred začetkom zdravljenja z zdravilom Imatinib Teva testirati glede okužbe z virusom hepatitisa B. Pri bolnikih s pozitivno serologijo na hepatitis B (vključno z bolniki z aktivno boleznijo) in bolnikih, pri katerih se med zdravljenjem test glede okužbe z virusom hepatitisa B izkaže za pozitivnega, se je treba pred začetkom zdravljenja posvetovati s strokovnjaki za obolenja jeter in zdravljenje hepatitisa B. Pri prenašalcih virusa hepatitisa B, pri katerih je potrebno zdravljenje z zdravilom Imatinib Teva, je treba med zdravljenjem in nekaj mesecev po njegovem zaključku skrbno spremljati pojav znakov in simptomov aktivne okužbe z virusom hepatitisa B (glej poglavje 4.8).
How to take Imatinib Teva 
Kako jemati zdravilo Imatinib Teva
Dose increases from 400 mg to 600 mg or 800 mg in patients with chronic phase disease, or from 600 mg to a maximum of 800 mg (given as 400 mg twice daily) in patients with accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response. 
Povečanje odmerka s 400 mg na 600 mg ali 800 mg pri bolnikih s kronično fazo bolezni ali s 600 mg na največ 800 mg (odmerjanih po 400 mg dvakrat na dan) pri bolnikih v pospešeni fazi ali v blastni krizi lahko pride v poštev, če bolnik nima hude neželene reakcije na zdravilo in hude nevtropenije ali trombocitopenije, ki ni povezana z levkemijo, v sledečih okoliščinah: napredovanje bolezni
Consolidation therapy 
Konsolidacijsko zdravljenje
The starting dose is 600 mg to be taken as 1 capsule of 400 mg plus 2 capsules of 100 mg once a day. 
Začetni odmerek je 600 mg, ki ga vzamete kot eno kapsulo po 400 mg in še 2 kapsuli po 100 mg enkrat na dan.
Using this approach, the estimated cumulative response rates for first-line treatment with imatinib improved from 12 months of therapy to 84 months of therapy as follows: CHR from 96.4% to 98.4% and CCyR from 69.5% to 87.2%, respectively. 
Na ta način pridobljene ocene kumulativnih stopenj odziva za zdravljenje z imatinibom kot zdravilom prvega izbora so med 12. in 84. mesecem zdravljenja pokazale izboljšanje in sicer: popolni hematološki odziv s 96,4 % na
ULN = upper limit of normal for the institution AST = aspartate aminotransferase 
IULN = zgornja meja normalnih vrednosti, specifična za ustanovo
The age of these patients ranged from 2 to 16 years and imatinib was given at dose 300 mg/m2 daily or doses ranging from 200 to 400 mg daily. 
Ti bolniki so bili stari od 2 do 16 let, imatinib pa so prejemali v odmerku 300 mg/m2 na dan ali v odmerkih od 200 mg do 400 mg na dan.
20x1 hard capsules 60 hard capsules 60x1 hard capsules 120 hard capsules 120x1 hard capsules 180x1 hard capsules 
20x1 trdih kapsul 60 trdih kapsul 60x1 trdih kapsul 120 trdih kapsul 120x1 trdih kapsul 180x1 trdih kapsul
Improvements were reported in cardiac, nervous, skin/subcutaneous tissue, respiratory/thoracic/mediastinal, musculoskeletal/connective tissue/vascular, and gastrointestinal organ systems. 
dihalnega/torakalnega/mediastinalnega organskega sistema, mišičnoskeletnega/vezivno tkivnega /žilnega organskega sistema in prebavil.
• Use about 200 ml for each 400 mg tablet. 
• Za vsako tableto po 400 mg potrebujete približno 200 ml vode.
The starting dose is 600 mg to be taken as 1 tablet of 400 mg plus 2 tablets of 100 mg or as 1 ½ tablets of 400 mg once a day. 
Začetni odmerek je 600 mg, ki ga vzamete kot eno tableto po 400 mg in še 2 tableti po 100 mg ali kot 1 ½ tablete po 400 mg enkrat na dan.
Major response at 84 months (%) * p<0.001, Fischer's exact test ** molecular response percentages are based on available samples Haematological response criteria (all responses to be confirmed after ≥ 4 weeks): WBC < 10 x 109/l, platelet < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement Cytogenetic response criteria: complete (0% Ph+ metaphases), partial (1-35%), minor (3665%) or minimal (66-95%). 
WBC < 10 x 109/l, trombociti < 450 x 109/l, mielociti+metamielociti < 5 % v krvi, brez blastov in promielocitov v krvi, bazofilci < 20 %, brez ekstramedularne prizadetosti Kriteriji citogenetičnega odziva: popolni (0 % Ph+ metafaz), delni (1-35 %), manjši (36-65 %) ali minimalni (66-95 %).
Rare 
redki:
Colitis, ileus, inflammatory bowel disease 
kolitis, ileus, vnetna bolezen črevesa pogostnost neznana:
Induction therapy II 
Indukcijsko zdravljenje II
The recommended dose of Imatinib Teva is 600 mg/day for adult patients with Ph+ ALL. 
Priporočeni odmerek zdravila Imatinib Teva pri odraslih bolnikih s Ph+ ALL je 600 mg/dan.
- if you experience bruising, bleeding, fever, fatigue and confusion when taking Imatinib Teva, 
- Če se v obdobju, ko jemljete zdravilo Imatinib Teva, pri vas pojavijo modrice, krvavitev, povišana telesna temperatura, utrujenost in zmedenost, se posvetujte z zdravnikom.
courses) 
IULN)
Not known: 
pogostnost neznana:
The age of these patients ranged from newborn to 14 years and imatinib was given at dose 50 mg daily or doses ranging from 400 to 520 mg/m2 daily. 
Ti bolniki so bili stari od starosti novorojenčka do 14 let, imatinib pa so prejemali v odmerku 50 mg na dan ali v odmerkih od 400 mg/m2 na dan do 520 mg/m2 na dan.
Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non-glandular stomach. 
Tarčni organi za neoplastične spremembe so bili: ledvice, sečni mehur, sečnica, leze prepucija in klitorisa, tanko črevo, obščitnične leze, nadledvične leze in ne-lezni del želodca.
(3 h), days 1-4; Mitoxantrone 10 mg/m2 i.v. 
(3 ure), 1.-4. dan; mitoksantron 10 mg/m2 i.v.
a ANC < 0.5 x 109/l and/or platelets < 10 x 109/l 
aANC < 0,5 x 109/l in/ali koncentracija trombocitov < 10 x 109/l
Active substances that may have their plasma concentration altered by imatinib Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indicating an inhibition of the CYP3A4 by imatinib. 
Imatinib povečuje povprečni Cmax in AUC simvastatina (substrat CYP3A4) 2-krat oziroma 3,5-krat, kar kaže na to, da imatinib zavira CYP3A4.
Your doctor will tell you exactly how many tablets of Imatinib Teva to take. 
Zdravnik vam bo natančno povedal, koliko tablet zdravila Imatinib Teva morate jemati.
- Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL). 
- z akutno limfoblastno levkemijo s prisotnim kromosomom Philadelphia (Ph pozitivna ALL).
5 Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML. 
5 O plevralnem izlivu so pogosteje poročali pri bolnikih z GIST in bolnikih s transformacijo KML (kronična mieloična levkemija v pospešeni fazi: KML-AP in kronična mieloična levkemija v blastni krizi: KML-BC) kot pri bolnikih s kroničnim potekom KML.
Psychiatric disorders Common 
Psihiatrične motnje pogosti:
Polyvinyl alcohol partially hydrolysed Macrogol 
- Obloga tablete vsebuje polivinilalkohol delno hidroliziran, makrogol, rumeni železov oksid
Triple IT therapy (age-adjusted): days 1, 29 VCR (1.5 mg/m2, IV): days 1, 29 
zdravljenje (prilagojeno na starost): 1. in 29.dan VCR (1,5 mg/m2/dan, i.v.
Very common (may affect more than 1 in 10 people) or common (may affect up to 1 in 10 people): 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov) ali pogosti (pojavijo se lahko pri največ
The effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival. 
Klinične študije pri kronični mieloični levkemiji Učinkovitost imatiniba temelji na stopnji celotnega hematološkega in citogenetičnega odziva ter preživetju brez napredovanja bolezni.
DEX 10 mg/m2 oral, days 1-5; 
DEX 10 mg/m2 peroralno, 1.-5. dan;
Active substances that may decrease imatinib plasma concentrations Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John's Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure. 
Snovi, ki inducirajo aktivnost CYP3A4 (na primer deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ali Hypericum perforatum, znan tudi pod imenom šentjanževka), lahko znatno zmanjšajo izpostavljenost imatinibu in s tem potencialno povečajo tveganje za neuspešnost zdravljenja.
All patients received imatinib and consolidation chemotherapy (see Table 4) after induction and the levels of bcr-abl transcripts were identical in the two arms at 8 weeks. 
Ravni transkriptov bcr-abl so bile po 8 tednih v obeh krakih enake.
The tablets are approximately 9 mm in diameter. 
Premer tablet je približno 9 mm.
If any of these affects you severely, tell your doctor. 
Če se pri vas kateri od zgoraj navedenih neželenih učinkov pojavi v hujši obliki, obvestite zdravnika.
Pack sizes of 20x1, 60x1, 120x1 or 180x1 film-coated tablets in perforated unit dose blisters. 
Škatle, ki vsebujejo po 20x1, 60x1, 120x1 ali 180x1 filmsko obloženih tablet v perforiranem pretisnem omotu.
Five (5) patients with MDS/MPD associated with PDGFR gene re-arrangements were reported in 4 publications. 
publikacijah so objavljeni podatki petih (5) bolnikov z MDS/MPD s preureditvijo gena za PDGFR.
Accelerated phase is defined by the presence of any of the following: blasts ≥ 15% but < 30% in blood or bone marrow, blasts plus promyelocytes ≥ 30% in blood or bone marrow (providing < 30% blasts), peripheral blood basophils ≥ 20%, platelets < 100 x 109/l unrelated to therapy. 
< 30 %, blasti in promielociti skupaj ≥ 30 % v krvi ali kostnem mozgu (pogoj: blasti < 30 %), bazofilci v periferni krvi ≥ 20 %, trombociti < 100 x 109/l ne glede na zdravljenje.
Nervous system disorders Very common 
Bolezni živčevja zelo pogosti:
Pack sizes of 30x1 or 90x1 film-coated tablets in perforated unit dose blisters. 
Škatle, ki vsebujejo po 30x1 ali 90x1 filmsko obloženih tablet v perforiranem pretisnem omotu.
• Feeling sick (nausea) with diarrhoea and vomiting, abdominal pain or fever (signs of bowel problems). 
• občutek slabosti s siljenjem na bruhanje (navzea) z drisko in bruhanjem, bolečine v trebuhu ali povišana telesna temperatura (znaki težav s črevesjem),
Whereas an estimated 96% (93%) of patients with CCyR (PCyR) at 12 months were free of progression to accelerated phase/blast crisis at 84 months, only 81% of patients without MCyR at 12 months were free of progression to advanced CML at 84 months (p<0.001 overall, p=0.25 between CCyR and PCyR). 
Za razliko od bolnikov s popolnim oziroma delnim citogenetičnim odzivom pri 12 mesecih, od katerih pri 96 % (za popolni odziv) oziroma 93 % (za delni odziv) ni prišlo do napredovanja bolezni v pospešeno fazo/blastno krizo po 84 mesecih, pa od bolnikov, ki so bili pri 12 mesecih brez pomembnega citogentičnega odziva, le pri 81 % ni prišlo do napredovanja bolezni v napredovalo fazo KML po 84 mesecih (p<0,001 skupno, p = 0,25 med popolnim in delnim citogenetičnim odzivom).
• Adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. 
(KML), s prisotnim kromosomom Philadelphia (bcr-abl) (Ph+), pri katerih presaditev kostnega mozga kot zdravljenje prve izbire ne pride v poštev;
4 weeks and more than 20 months. 
20 mesecev.
6+7 Abdominal pain and gastrointestinal haemorrhage were most commonly observed in GIST patients. 
Bolečine v trebuhu in krvavitev iz prebavil so najpogosteje opažali pri bolnikih z GIST.
ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l, then resume treatment at 300 mg. 
dokler ni ANC ≥ 1 x 109/l in koncentracija trombocitov ≥ 20 x 109/l, nato spet začnite zdravljenje z odmerkom 300 mg.
600 mg to be taken as 1 tablet of 400 mg plus 2 tablets of 100 mg or as 1 ½ tablets of 400 mg once a day. 
- 400 mg vzamete kot 1 tableto enkrat na dan, 600 mg vzamete kot 1 tableto po 400 mg in še 2 tableti po 100 mg ali kot 1 ½ tablete po 400 mg enkrat na dan.
If your daily dose is 800 mg (8 capsules), you should take 4 capsules in the morning and 4 capsules in the evening. 
Če je vaš dnevni odmerek 800 mg (8 kapsul), morate vzeti 4 kapsule zjutraj in 4 kapsule zvečer.
The dose of 340 mg/m2 daily is recommended for children with chronic phase CML and advanced phase CML (not to exceed the total dose of 800 mg). 
oziroma z napredovalimi fazami KML je priporočeni odmerek 340 mg/m2 na dan (ne sme preseči celotnega odmerka 800 mg).
Do not use any pack that is damaged or shows signs of tampering. 
Ne uporabljajte tega zdravila, če opazite vidne znake kvarjenja.
DEX 10 mg/m2 oral, days 1-5; CP 200 mg/m2 i.v., days 3, 4, 5; 
DEX 10 mg/m2 peroralno, 1.-5. dan; CP 200 mg/m2 i.v., 3., 4., 5. dan;
The recommended dosage of Imatinib Teva is 400 mg/day for adult patients in chronic phase CML. 
Priporočeno odmerjanje zdravila Imatinib Teva za odrasle bolnike v kronični fazi KML je 400 mg/dan.
If your daily dose is 800 mg (2 capsules), you should take one capsule in the morning and a second capsule in the evening. 
Če je vaš dnevni odmerek 800 mg (2 kapsuli), morate vzeti eno kapsulo zjutraj in eno kapsulo zvečer.
The dose is 800 mg per day (2 capsules), to be taken as 1 capsule in the morning and a second capsule in the evening. 
Odmerek je 800 mg na dan (2 kapsuli), ki ga vzamete kot eno kapsulo zjutraj in eno kapsulo zvečer.
If your daily dose is 800 mg (2 tablets), you should take one tablet in the morning and a second tablet in the evening. 
Če je vaš dnevni odmerek 800 mg (2 tableti), morate vzeti 1 tableto zjutraj in 1 tableto zvečer.
DEX 10 mg/m2 oral, days 1-5; CP 200 mg/m2 i.v., days 3-5; 
DEX 10 mg/m2 peroralno, 1.-5. dan; CP 200 mg/m2 i.v., 3.-5. dan;
The dose is 800 mg per day (2 tablets), to be taken as 1 tablet in the morning and a second tablet in the evening. 
Odmerek je 800 mg na dan (2 tableti), ki ga vzamete kot eno tableto zjutraj in eno tableto zvečer.
Your doctor will tell you exactly how many capsules of Imatinib Teva to take. 
Zdravnik vam bo natančno povedal, koliko kapsul zdravila Imatinib Teva morate jemati.
Major cytogenetic response2 
Pomemben citogenetični odziv2
diagnosis 
ZDRAVILA
Imatinib Teva 100 mg film-coated tablets are available in pack sizes of 20x1, 60x1, 120x1 or 180x1 film-coated tablets in perforated unit dose blisters. 
Zdravilo Imatinib Teva 100 mg filmsko obložene tablete je pakirano v škatli po 20x1, 60x1, 120x1 ali 180x1 v perforiranih pretisnih omotih.
Pleuritic pain, pulmonary fibrosis, pulmonary hypertension, pulmonary haemorrhage 
plevritična bolečina, pljučna fibroza, pljučna hipertenzija, pljučna krvavitev pogostnost neznana:
Based on the recovery of compound(s) after an oral 14C-labelled dose of imatinib, approximately 81% of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). 
% odmerka odstranilo iz telesa v 7 dneh z blatom (68 % odmerka) in urinom (13 % odmerka).
Imatinib Teva 100 mg film-coated tablets Each film-coated tablet contains 100 mg of imatinib (as mesilate). 
Imatinib Teva 100 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 100 mg imatiniba (v obliki mesilata).
Tumour haemorrhage/tumour necrosis* 
krvavitev iz tumorja/nekroza tumorja*
Titanium dioxide (E171) Iron oxide red (E172) 
Ovojnine kapsule želatina titanov dioksid (E171) rumeni železov oksid (E172)
Pack sizes of 60 or 120, hard capsules in blisters. 
Škatla, ki vsebuje po 60 ali 120, trdih kapsul v pretisnem omotu.
What Imatinib Teva looks like and contents of the pack Imatinib Teva 400 mg hard capsules are non transparent orange capsules with black marking 7630 on capsule body and black marking TEVA on capsule cap. 
Zdravilo Imatinib Teva 400 mg trde kapsule so neprozorne oranžne kapsule s črno oznako 7630 na jedru in s črno oznako Teva na pokrovčku kapsule.
The starting dose is 400 mg, to be taken as 4 capsules once a day. 
Začetni odmerek je 400 mg, ki ga vzamete kot 4 kapsule enkrat na dan.
Fluid retention and oedema, fatigue 
zastajanje tekočine in edemi, utrujenost pogosti:
• Bruising. 
• srbenje,
Cytogenetic abnormalities were evaluated in 117 of the total population of 176 patients. 
objavljenih opisih primerov in skupinah primerov, je prejemalo imatinib v odmerkih od 75 mg do 800 mg na dan. Citogenetske nepravilnosti so pregledali pri 117 bolnikih od celotne populacije 176 bolnikov.
Imatinib Teva 400 mg film-coated tablets Each film-coated tablet contains 400 mg of imatinib (as mesilate). 
Imatinib Teva 400 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 400 mg imatiniba (v obliki mesilata).
Hypokalaemia, increased appetite, hypophosphataemia, decreased appetite, dehydration, gout, hyperuricaemia, hypercalcaemia, hyperglycaemia, hyponatraemia 
zmanjšan apetit, dehidracija, protin, hiperurikemija, hiperkalciemija, hiperglikemija, hiponatriemija redki:
The capsule shell is composed of gelatin, titanium dioxide (E171), iron oxide yellow (E172) and iron oxide red (E172). 
- Ovojnica kapsule vsebuje želatino, titanov dioksid (E171), rumeni železov oksid (E172), rdeči železov oksid (E172).
Partial 
zmedenost
In the event of recurrence of ANC < 1.0 x109/l and/or platelets < 50 x 109/l, repeat step 1 and resume imatinib at reduced dose of 400 mg. 
Če se pojav/a ANC < 1,0 x 109/l in/ali koncentracija trombocitov < 50 x 109/l ponovi/ta, ponovite točko 1 in spet začnite zdravljenje z imatinibom z zmanjšanim odmerkom 400 mg.
Paediatric use 
Uporaba v pediatriji
Study AUS01 Induction-consolidation therapy 
Študija AUS01
• Muscle spasms with a fever, red-brown urine, pain or weakness in your muscles (signs of muscle problems). 
• bolečine v želodcu z občutkom slabosti s siljenjem na bruhanje (navzea), • mišični spazmi z vročino, rdeče-rjavo obarvan urin, boleče ali oslabele mišice (znaki težav z mišicami),
Imatinib Teva 100 mg hard capsules imatinib 
Imatinib Teva 100 mg trde kapsule imatinib
• Chest pain, irregular heart rhythm (signs of heart problems). 
1.000 bolnikov): • bolečine v prsnem košu, neredno bitje srca (znaki težav s srcem),
Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain6 
navzea, driska, bruhanje, dispepsija, bolečine v trebuhu6
What Imatinib Teva looks like and contents of the pack Imatinib Teva 100 mg hard capsules are non transparent orange capsules with black marking 7629 on capsule body and black marking TEVA on capsule cap. 
Zdravilo Imatinib Teva 100 mg trde kapsule so neprozorne oranžne kapsule s črno oznako 7629 na jedru in s črno oznako Teva na pokrovčku kapsule.
Imatinib Teva 100 mg film-coated tablets are available in pack sizes of 60 or 120 film-coated tablets in blisters. 
Zdravilo Imatinib Teva 100 mg filmsko obložene tablete je pakirano v škatli po 60 ali 120 filmsko obloženih tablet v pretisnem omotu.
The recommended dosage of Imatinib Teva is 600 mg/day for adult patients in accelerated phase. 
Priporočeno odmerjanje zdravila Imatinib Teva za odrasle bolnike v pospešeni fazi je 600 mg/dan.
Imatinib Teva 400 mg hard capsules imatinib 
Imatinib Teva 400 mg trde kapsule imatinib
Consolidation (de novo Ph+ ALL) 
Indukcijsko zdravljenje (novo odkrita Ph+ ALL)
Iron oxide yellow (E172) Talc 
rdeči železov oksid (E172)
doses)iii: days 2, 3, 16, and 17 
ali peroralno vsakih 6 ur x 6 odmerkov) iii: 2., 3., 16. in 17. dan trojno i.t.
Imatinib Teva 100 mg hard capsules are available in pack sizes of 60 or 120 hard capsules in blisters. 
Zdravilo Imatinib Teva 100 mg trde kapsule je pakirano v škatli po 60 ali 120 trdih kapsul v pretisnem omotu.
This was a population of heavily pretreated patients, as 46% had received prior BMT and 73% a prior multi-agent chemotherapy. 
46 % imelo presaditev kostnega mozga (BMT - bone marrow transplantation), 73 % pa kemoterapijo z več zdravili.
Posology for DFSP The recommended dose of Imatinib Teva is 800 mg/day for adult patients with DFSP. 
Priporočeni odmerek zdravila Imatinib Teva pri odraslih bolnikih z DFSP je 800 mg/dan.
The starting dose is 100 mg, to be taken as 1 tablet of 100 mg once a day. 
Začetni odmerek je 100 mg, ki ga vzamete kot eno tableto po 100 mg enkrat na dan.
Imatinib Teva 400 mg hard capsules are available in pack sizes of 30x1 or 90x1 hard capsules in perforated unit dose blisters. 
Zdravilo Imatinib Teva 400 mg trde kapsule je pakirano v škatli po 30x1 ali 90x1 trdih kapsul v perforiranem pretisnem omotu.
Imatinib Teva 100 mg hard capsules Each hard capsule contains 100 mg of imatinib (as mesilate). 
Imatinib Teva 100 mg trde kapsule Ena kapsula vsebuje 100 mg imatiniba (v obliki mesilata).
Imatinib Teva 400 mg hard capsules Each hard capsule contains 400 mg of imatinib (as mesilate). 
Imatinib Teva 400 mg trde kapsule Ena kapsula vsebuje 400 mg imatiniba (v obliki mesilata).
The starting dose is 400 mg, to be taken as 4 tablets once a day. 
Začetni odmerek je 400 mg, ki ga vzamete kot 4 tablete enkrat na dan.
Imatinib Teva 400 mg hard capsules 
Imatinib Teva 400 mg trde kapsule
Pack sizes of 20x1, 60x1, 120x1 or 180x1 hard capsules in perforated unit dose blisters. 
Škatla, ki vsebuje po 20x1, 60x1, 120x1 ali 180x1 trdih kapsul v perforiranem pretisnem omotu.
Imatinib Teva 100 mg hard capsules are available in pack sizes of 20x1, 60x1, 120x1 or 180x1 hard capsules in perforated unit dose blisters. 
Zdravilo Imatinib Teva 100 mg trde kapsule je pakirano v škatli po 20x1, 60x1, 120x1 ali 180x1 trdih kapsul v perforiranem pretisnem omotu.
You may become more sensitive to the sun while taking Imatinib Teva. 
Med jemanjem zdravila Imatinib Teva lahko postanete občutljivejši na sonce.
The starting dose is 100 mg, to be taken as 1 capsule of 100 mg once a day. 
Začetni odmerek je 100 mg, ki ga vzamete kot eno kapsulo po 100 mg enkrat na dan.
EU/1/12/808/001 20 x 1 film-coated tablets EU/1/12/808/002 60 film-coated tablets EU/1/12/808/003 60 x 1 film-coated tablets EU/1/12/808/004 120 film-coated tablets EU/1/12/808/005 120 x 1 film-coated tablets EU/1/12/808/006 180 x 1 film-coated tablets EU/1/12/808/007 20 x 1 film-coated tablets EU/1/12/808/008 60 film-coated tablets EU/1/12/808/009 60 x 1 film-coated tablets EU/1/12/808/010 120 film-coated tablets EU/1/12/808/011 120 x 1 film-coated tablets EU/1/12/808/012 180 x 1 film-coated tablets 
EU/1/12/808/001 20x1 filmsko obloženih tablet EU/1/12/808/002 60 filmsko obloženih tablet EU/1/12/808/003 60x1 filmsko obloženih tablet EU/1/12/808/004 120 filmsko obloženih tablet EU/1/12/808/005 120x1 filmsko obloženih tablet EU/1/12/808/006 180x1 filmsko obloženih tablet EU/1/12/808/007 20x1 filmsko obloženih tablet EU/1/12/808/008 60filmsko obloženih tablet EU/1/12/808/009 60x1 filmsko obloženih tablet EU/1/12/808/010 120 filmsko obloženih tablet EU/1/12/808/011 120x1 filmsko obloženih tablet EU/1/12/808/012 180x1 filmsko obloženih tablet
Imatinib Teva 400 mg film-coated tablets are available in pack sizes of 30x1or 90x1 film-coated tablets in perforated unit dose blisters. 
Zdravilo Imatinib Teva 400 mg filmsko obložene tablete je pakirano v škatli po 30x1 ali 90x1 v perforiranih pretisnih omotih.